Rocket Pharmaceuticals, Inc. (RCKT) — Financial statements
Income statement, balance sheet, and cash flow for Rocket Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 11 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -11 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 142↓17.1% | 171↓8.1% | 186↑12.5% | 166↑32.0% | 125 | |
| General & Administrative Expenses | 87↓15.2% | 102↑39.1% | 73↑24.7% | 59↑40.7% | 42 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 87↓15.2% | 102↑39.1% | 73↑24.7% | 59↑40.7% | 42 | |
| Other Expenses | -11 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 217↓20.4% | 273↑5.2% | 260↑15.7% | 224↑34.1% | 167 | |
| Total Costs & Expenses | 229↓16.4% | 273↑5.2% | 260↑15.7% | 224↑34.1% | 167 | |
| Operating Results | ||||||
| Operating Income | -229↑16.4% | -273↓5.2% | -260↓15.7% | -224↓34.1% | -167 | |
| Depreciation & Amortization | 11↑17.6% | 9↑32.1% | 7↑13.3% | 6↑16.6% | 5 | |
| EBITDA | -210↑15.1% | -247↓4.6% | -237↓10.7% | -214↓35.4% | -158 | |
| EBIT | -221↑13.9% | -257↓5.4% | -244↓10.8% | -220↓34.8% | -163 | |
| Interest & Other Income | ||||||
| Net Interest Income | 9↓46.6% | 16↑16.1% | 14↑610.3% | 2↑170.2% | -3 | |
| Interest Income | 11↓41.7% | 18↑14.3% | 16↑309.8% | 4↑26.8% | 3 | |
| Interest Expense | 2↑0.3% | 2↑0.6% | 2↓1.8% | 2↓67.6% | 6 | |
| Non-Operating Income | -7↑55.4% | -16↓2.5% | -16↓263.2% | -4↓7.9% | -4 | |
| Other Income / Expenses | 5↓62.7% | 14↑2.8% | 14↑467.1% | 2↑236.2% | -2 | |
| Income Before Tax | -223↑13.8% | -259↓5.4% | -246↓10.7% | -222↓31.2% | -169 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -223↑13.8% | -259↓5.4% | -246↓10.7% | -222↓31.2% | -169 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -223↑13.8% | -259↓5.4% | -246↓10.7% | -222↓31.2% | -169 | |
| Bottom-Line Net Income | -223↑13.8% | -259↓5.4% | -246↓10.7% | -222↓31.2% | -169 | |
| EPS (Basic) | -2.01↑26.4% | -2.73↑6.5% | -2.92↑10.4% | -3.26↓21.6% | -2.68 | |
| EPS (Diluted) | -2.01↑26.4% | -2.73↑6.5% | -2.92↑10.4% | -3.26↓21.6% | -2.68 | |
| Weighted Average Shares | 111↑17.2% | 95↑12.9% | 84↑23.3% | 68↑7.8% | 63 | |
| Weighted Average Diluted Shares | 111↑17.2% | 95↑12.9% | 84↑23.3% | 68↑7.8% | 63 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.